Anderly C. Chueh
Affiliations: | The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia |
Area:
Epigenetic Enzymes, Mitotic Signaling, Translational Cancer Biology, Drug Development, Biomarker IdentificationGoogle:
"Anderly Chueh"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| KH Andy Choo | grad student | 2003-2008 | University of Melbourne |
| Lee H. Wong | grad student | 2003-2008 | |
| John M. Mariadason | post-doc | 2009-2013 | Ludwig Institute for Cancer Research |
| Ian P. Street | research scientist | 2016- | Walter and Eliza Hall Institute of Medical Research |
| Antony W. Burgess | research scientist | 2014-2016 | Walter and Eliza Hall Institute of Medical Research |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chüeh AC, Tse JWT, Dickinson M, et al. (2023) Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 29: 3826 |
| Sharma S, Chung CY, Uryu S, et al. (2023) Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chemical Biology |
| Tögel L, Nightingale R, Wu R, et al. (2023) Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports. 13: 2422 |
| Chionh F, Gebski V, Al-Obaidi SJ, et al. (2022) VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports. 12: 1238 |
| Chüeh AC, Advani G, Foroutan M, et al. (2021) CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. Oncogene |
| Grohmann C, Walker F, Devlin M, et al. (2021) Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. Cell Death & Disease. 12: 268 |
| Tögel L, Nightingale R, Wu R, et al. (2018) DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports. 8: 1767 |
| Chüeh AC, Liew MS, Russell PA, et al. (2017) Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget. 8: 74036-74048 |
| Chüeh AC, Tse JW, Dickinson M, et al. (2017) ATF3 repression of BCL-XL determines apoptotic sensitivity toHDAC inhibitors across tumour types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Tögel L, Nightingale R, Chueh AC, et al. (2016) Dual targeting of bromodomain and extra-terminal domain proteins, and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells. Molecular Cancer Therapeutics |